The Complete Versus culprit-Lesion only PRimary PCI Trial (CvLPRIT), which was presented at last August's European Society of Cardiology Conference, has demonstrated that patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction, and have significant multivessel disease should be fully revascularized in the acute setting. 1 In their study entitled ''Percutaneous coronary intervention rates and associated independent predictors for progression of nontarget lesions in patients with diabetes mellitus after drug-eluting stent implantation,'' Wang et al 2 take this a step forward in diabetic patients to answer some further burning questions; how much attention should be given to nonculprit, nonsignificant lesions, discovered at the time of index angiography? More specifically, what are the factors that may lead to rapid progression of these ''benign'' lesions in the future (1-3 years timeline defined by this study) to necessitate intervention?
Five variables stood out statistically, SYNTAX score, insulin use, obesity, reduced high-density lipoprotein cholesterol levels, and statin use. In the era of limited health budgets, the above-mentioned factors provide useful guidance for resource allocation. This includes identifying patient subgroups that require close follow-up and early intervention as well as identifying factors that need to be treated aggressively to prevent a return to the catheterization laboratory.
It would also be interesting to see whether in the long term a combination of the above-mentioned factors leads to stent complications, with adverse plaque remodeling and in-stent restenosis. A high SYNTAX score has already been identified in an article in this journal, to correlate with future major adverse cardiac events, in patients undergoing primary PCI. 3 Furthermore, on the issue of lipid modification, these results may provide incentive for lower lipid targets and aggressive lipid-lowering therapy, using novel agents such as the proprotein convertase subtilisin/kexin type 9 inhibitors that may be better tolerated than statins at higher doses. 4 Is there a tool that we can use to help use model the progression of nonsignificant lesions in the above-mentioned risk groups and, in effect, predict when we should be considering another coronary investigation? The Fractional Flow Reserve-Guided PCI versus Medical Therapy (FAME II) study has demonstrated the prognostic importance of measuring fractional flow reserve (FFR) in guiding angioplasty in stable coronary artery disease. 5 The use of FFR in this patient group will not only ensure that all prognostically significant lesions are not missed but will also provide a comparable variable to help answer the question mentioned previously. This investigative modality may also be supplemented with other powerful tools, such as Intravascular Ultrasound or Optical Coherence Tomography, to delineate more closely, and profile lesion anatomy in detail, looking for unique features.
